The PCSK9 targeted drug market is about to explode, and the blockbuster product of 1 billion US dollars has appeared

Author: Memories

PCSK9, the preprotein convertase subtilisin 9, also known as neuronal apoptosis-regulating convertase-1 (NARC1), is mainly expressed in the liver, small intestine and kidney, and is the ninth member of the preprotein convertase family.

3 PCSK9-targeted drugs in the world

At present, PCSK9 is recognized as the most effective star lipid-lowering target after statins

Overall, two older drugs, Repatha and Praluent, did not perform as originally expected due to high listing prices and payment constraints, and the companies lowered their prices from about $14,000 at launch to lower prices.

It is worth mentioning that at the beginning of this year, GlobalData analysts had forecast the sales of these three drugs: Leqvio is expected to surpass Amgen's Repatha and Sanofi/Regeneron's Praluent in sales by virtue of the convenience of treatment, 2027 Annual sales of Repatha and Praluent are expected to reach $2.

14 companies including Hengrui and Junshi have already deployed a number of them and entered clinical phase III

At present, more and more companies are optimistic about the PCSK9 targeted drug market and have developed a variety of drugs under research, as shown in the table below

Developed by Lib Therapeutics, lerodalcibep is a recombinant fusion protein containing the PCSK9 binding domain and human serum albumin, which extends its half-life to 12-15 days and allows for administration as a monthly injection

In addition, with the deepening of research, in addition to lowering blood lipids, PCSK9-targeted drugs are also expected to be used to treat metabolic diseases such as diabetes and non-alcoholic fatty liver disease, as well as diseases closely related to metabolism such as Alzheimer's disease, tumors,